MARKET

LEXX

LEXX

Lexaria Bioscience Corp
NASDAQ
0.5452
-0.0148
-2.64%
Opening 14:10 12/30 EST
OPEN
0.5432
PREV CLOSE
0.5600
HIGH
0.5620
LOW
0.4900
VOLUME
500.69K
TURNOVER
--
52 WEEK HIGH
2.430
52 WEEK LOW
0.4600
MARKET CAP
13.57M
P/E (TTM)
-0.8244
1D
5D
1M
3M
1Y
5Y
1D
Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform
TipRanks · 3h ago
Lexaria Bioscience Reports Final Phase 1b GLP-1-H24-4 Results Showing DHT-Semaglutide Demonstrates Comparable Or Improved Safety, Tolerability And Body Composition vs. Rybelsus
Benzinga · 5h ago
Lexaria releases additional results from Phase 1b study GLP-1-H24-4
TipRanks · 5h ago
Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study
Reuters · 5h ago
Lexaria Bioscience files to sell 2.75M shares of common stock for holders
TipRanks · 21h ago
Weekly Report: what happened at LEXX last week (1222-1226)?
Weekly Report · 1d ago
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday
Benzinga · 4d ago
Lexaria Bioscience Price Target Cut to $1.50/Share From $4.00 by HC Wainwright & Co.
Dow Jones · 4d ago
More
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

Webull offers Lexaria Bioscience Corp stock information, including NASDAQ: LEXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEXX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEXX stock methods without spending real money on the virtual paper trading platform.